What is the 13F Pro Quality Score for LMAT?

13F Pro ranks LEMAITRE VASCULAR INC (LMAT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LMAT's current score at https://13fpro.ai/company/LMAT (free sign-up required for the full ranking).

Which hedge funds own the most LMAT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of LMAT include BlackRock,, Conestoga Capital Advisors,, FIRST ADVISORS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/LMAT as soon as new 13F filings post.

Where does 13F Pro source LMAT data?

All LEMAITRE VASCULAR INC fundamentals and ownership data come directly from SEC EDGAR. LEMAITRE VASCULAR INC files with the SEC under CIK 1158895. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LMAT in?

LEMAITRE VASCULAR INC (LMAT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives LMAT's revenue?

Per LEMAITRE VASCULAR INC's latest 10-Q filed with the SEC on 2026-08-05, the biggest revenue drivers are: Americas ($43.5M, +5% YoY); Europe, Middle East and Africa ($22.1M, +18% YoY); Asia Pacific ($4.8M, +18% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/LMAT.

What are LMAT's largest expenses?

LEMAITRE VASCULAR INC's latest 10-Q reports these as the largest expense items: Sales and marketing ($14.4M, -3% YoY); General and administrative ($11.1M, +7% YoY); Research and development ($4.8M, +37% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is LMAT research updated on 13F Pro?

LMAT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

LEMAITRE VASCULAR INC(LMAT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1158895 LMAT stock profile & AI dashboard →

13F Pro Quality Score

66.0/100

Rank #449 of 2,961 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

67.1/100

Profitability

88.4/100

Balance Sheet

87.0/100

Earnings Quality

68.3/100

Free Cash Flow

82.0/100

Institutional Flow

35.4/100

Revenue Scale

27.5/100

Dilution Risk

31.5/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why LMAT Scores 66/100

exact factor attribution · 2026-09-11

LMAT's composite is driven by profitability and free cash flow, held back by scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Profitability

+5.8 pts

88th pct

Free cash flow

+4.8 pts

82th pct

Capital efficiency

+3.7 pts

87th pct

Revenue growth

+3.4 pts

67th pct

Earnings quality

+1.8 pts

68th pct

Earnings growth

+1.6 pts

81th pct

Institutional flow

-0.7 pts

35th pct

Shareholder dilution

-0.9 pts

32th pct

Scale

-3.4 pts

28th pct

Latest change (2026-08-05): 69 → 67 · ↓ Revenue growth 71→56; ↓ Earnings growth 80→66

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

LMAT Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for LEMAITRE VASCULAR INC (LMAT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LMAT at 66.0/100 on a 32-signal composite quality model, placing it at rank #449 of 2,961 stocks — the top 25% of the AI-ranked universe. LMAT scores in the top quartile across profitability (88.4), balance sheet strength (87.0), free cash flow (82.0). Areas of concern include revenue scale (27.5) and institutional flow (35.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 31.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), LEMAITRE VASCULAR INC reports quarterly revenue of $70.4M, net income of $17.1M, an operating margin of 29.0%. Top institutional holders of LMAT by reported 13-F value include BlackRock, Conestoga Capital Advisors, FIRST ADVISORS, based on the most recent SEC filings. LMAT trades on the Nasdaq exchange and files with the SEC under CIK 1158895. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LMAT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LEMAITRE VASCULAR INC directly from SEC EDGAR. LEMAITRE VASCULAR INC's 13F Pro composite quality score has ranged between 48 and 71 since 2021, currently 66.0 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

What's Driving LMAT's Business? Latest 10-Q Breakdown

✓ 15/15 datapoints verified

AI-extracted from LEMAITRE VASCULAR INC's 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net sales rose 10% YoY to $70.4M with gross margin up 210bps to 72.1%, as growth was broad-based across all three geographies led by grafts and shunts.

Biggest Revenue Drivers

Americas$43.5M+5% YoY

Increased sales of grafts, shunts, and patches, offset by decreased catheter sales

Europe, Middle East and Africa$22.1M+18% YoY

Increased sales of grafts, shunts, patches, and valvulotomes, offset by decreased catheters

Biggest Revenue Drivers

Total revenue: $70.4M+10% YoY

Americas$43.5M+5% YoY

Increased sales of grafts, shunts, and patches, offset by decreased catheter sales

Europe, Middle East and Africa$22.1M+18% YoY

Increased sales of grafts, shunts, patches, and valvulotomes, offset by decreased catheters

Asia Pacific$4.8M+18% YoY

Increased sales of clips, grafts, and catheters

Largest Expense Items

Sales and marketing$14.4M-3% YoY

Lower compensation, commissions, and contest expenses

General and administrative$11.1M+7% YoY

Higher headcount and wage-driven compensation, and increased professional fees

Research and development$4.8M+37% YoY

Higher third-party service fees and supplies for the allograft tissue transfer to Burlington, plus new Billerica warehouse start-up costs

Margins: Gross margin rose 210bps to 72.1%, driven by sales price increases, favorable product mix, and lower shipping costs, partially offset by unfavorable manufacturing efficiencies and higher excess and obsolescence charges.

Watch Items from the Filing

FDA issued a warning letter after an April 2025 Artegraft facility inspection; a June 2026 re-inspection identified additional new observations, with remediation ongoing.
Biologics represented 55% of worldwide sales in Q2 2026, a significant concentration in a product category the company calls differentiated and growing.
Direct-to-hospital sales were 95% of total net sales in the quarter, reflecting the company's strategy of transitioning distributor markets to direct sales.
$172.5M of 2.50% convertible senior notes outstanding; conversion price adjusts downward each time the quarterly dividend exceeds $0.16/share, currently $0.25.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$70.4M

Net Income

Q2 2026

$17.1M

Free Cash Flow

Q2 2026

$13.7M

Operating Margin

Q2 2026

29.0%

ROIC

Q2 2026

19.4%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+13.5% YoY

$249.6MFY 2025

FY22 $161.7MFY23 $193.5MFY24 $219.9MFY25 $249.6M

Net Income

+31.1% YoY

$57.7MFY 2025

FY22 $20.6MFY23 $30.1MFY24 $44.0MFY25 $57.7M

Operating Income

+30.0% YoY

$67.9MFY 2025

FY22 $26.8MFY23 $36.7MFY24 $52.3MFY25 $67.9M

EPS (Diluted)

+30.6% YoY

$2.52FY 2025

FY22 $0.93FY23 $1.34FY24 $1.93FY25 $2.52

Total Assets

+11.6% YoY

$615.7MFY 2025

FY22 $310.5MFY23 $346.8MFY24 $551.8MFY25 $615.7M

Op. Cash Flow

+84.1% YoY

$81.3MFY 2025

FY22 $25.4MFY23 $36.8MFY24 $44.1MFY25 $81.3M

Free Cash Flow

+100.4% YoY

$74.5MFY 2025

FY22 $22.1MFY23 $29.5MFY24 $37.2MFY25 $74.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$249.6M +13.5%	$219.9M +13.6%	$193.5M +19.7%	$161.7M +4.7%	$154.4M +19.4%	$129.4M
Net Income	$57.7M +31.1%	$44.0M +46.3%	$30.1M +45.9%	$20.6M -23.3%	$26.9M +26.8%	$21.2M
Operating Income	$67.9M +30.0%	$52.3M +42.3%	$36.7M +36.8%	$26.8M -26.3%	$36.4M +26.5%	$28.8M
EPS (Diluted)	$2.52 +30.6%	$1.93 +44.0%	$1.34 +44.1%	$0.93 -25.6%	$1.25 +20.2%	$1.04
Total Assets	$615.7M +11.6%	$551.8M +59.1%	$346.8M +11.7%	$310.5M +6.0%	$292.8M +15.8%	$252.8M
Operating Cash Flow	$81.3M +84.1%	$44.1M +20.1%	$36.8M +44.8%	$25.4M -27.7%	$35.1M +0.9%	$34.8M
Free Cash Flow	$74.5M +100.4%	$37.2M +26.0%	$29.5M +33.1%	$22.1M -26.7%	$30.2M -5.0%	$31.8M

Get alerted when LMAT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for LEMAITRE VASCULAR INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LMAT

BlackRock, Inc.
$314.1M3,272,973 sh
Conestoga Capital Advisors, LLC
$131.2M1,367,513 sh
FIRST TRUST ADVISORS LP
$104.9M1,093,502 sh
CONGRESS ASSET MANAGEMENT CO /MA
$92.5M963,706 sh
VANGUARD CAPITAL MANAGEMENT LLC
$91.5M953,437 sh
STATE STREET CORP
$86.5M901,416 sh
Copeland Capital Management, LLC
$80.6M839,463 sh
GEODE CAPITAL MANAGEMENT, LLC
$75.7M788,835 sh
PRICE T ROWE ASSOCIATES INC /MD/
$72.5M755,142 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$58.0M604,833 sh

Fund	Value	Shares
BlackRock, Inc.	$314.1M	3,272,973
Conestoga Capital Advisors, LLC	$131.2M	1,367,513
FIRST TRUST ADVISORS LP	$104.9M	1,093,502
CONGRESS ASSET MANAGEMENT CO /MA	$92.5M	963,706
VANGUARD CAPITAL MANAGEMENT LLC	$91.5M	953,437
STATE STREET CORP	$86.5M	901,416
Copeland Capital Management, LLC	$80.6M	839,463
GEODE CAPITAL MANAGEMENT, LLC	$75.7M	788,835
PRICE T ROWE ASSOCIATES INC /MD/	$72.5M	755,142
VANGUARD PORTFOLIO MANAGEMENT LLC	$58.0M	604,833

Companies Similar to LMAT

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

VCEL

Vericel Corp

AI score

Very similar · 23 shared holders

Conestoga Capital Advisors, LLC CONGRESS ASSET MANAGEMENT CO /MA GENEVA CAPITAL MANAGEMENT LLC

IRMD

IRADIMED CORP

AI score

Similar quality profile · 22 shared holders

Copeland Capital Management, LLC KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC Ranger Investment Management, L.P.

INVA

Innoviva, Inc.

AI score

Similar quality profile · 13 shared holders

CAMDEN ASSET MANAGEMENT L P /CA Susquehanna Portfolio Strategies, LLC Linden Thomas Advisory Services, LLC

VCYT

VERACYTE, INC.

AI score

Similar quality profile · 12 shared holders

OBERWEIS ASSET MANAGEMENT INC/RICE HALL JAMES & ASSOCIATES, LLC SEGALL BRYANT & HAMILL, LLC

LGND

LIGAND PHARMACEUTICALS INC

AI score

Similar quality profile · 18 shared holders

CONGRESS ASSET MANAGEMENT CO /MA Ranger Investment Management, L.P.RICE HALL JAMES & ASSOCIATES, LLC

LIVN

LivaNova PLC

AI score

Similar quality profile · 17 shared holders

CONGRESS ASSET MANAGEMENT CO /MA KENNEDY CAPITAL MANAGEMENT LLC READYSTATE ASSET MANAGEMENT LP

TMDX

TransMedics Group, Inc.

AI score

Similar quality profile · 10 shared holders

READYSTATE ASSET MANAGEMENT LP TENOR CAPITAL MANAGEMENT Co., L.P.CONGRESS ASSET MANAGEMENT CO /MA

UFPT

UFP TECHNOLOGIES INC

AI score

Similar quality profile · 24 shared holders

CONGRESS ASSET MANAGEMENT CO /MA GENEVA CAPITAL MANAGEMENT LLC Annex Advisory Services, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LMAT on your watchlist

Track score changes the day LEMAITRE VASCULAR INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LMAT a good stock to buy?

13F Pro's AI-powered analysis of LEMAITRE VASCULAR INC (LMAT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LMAT are available on the LMAT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. LMAT is classified as a small company.

Which hedge funds own LMAT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LMAT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LEMAITRE VASCULAR INC's investment landscape.